Horizon Discovery and Cellesce presented a joint poster at the ELRIG Drug Discovery Exhibition and Conference which took place 9th – 10th October in London. The last panel shows data confirming the activity of Trametinib  and demonstrating the differential effects of Dabrafenib from two lines of Cellesce expanded organoids. Both drugs, which can be used in combination to overcome resistance have been approved for clinical use.

Subsequently Horizon Discovery has published a proof of concept case study – High-Throughput Screening in Colorectal Organoids.


0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *